Is Insight Molecular Diagnostics Inc. (IMDX) a Buy, Sell, or Hold?
NASDAQ : IMDX
Insight Molecular Diagnostics Inc.
$4.74 USD
$0.03 (0.64%)
- Volume
- 39.1K
- Average Volume
- 349.82K
- Market Capitalization
- $127.23M
- P/E Ratio
- -3.13
- Dividend Yield
- 0.00%
- Price Target
- $12.00
- Year High
- $8.51
- Year Low
- $2.33
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.54
Company Overview
NASDAQ
Joshua Riggs
Medical - Diagnostics & Research
Healthcare
IMDX
58
US
USD
Liquidity Metrics
-0.29
2.54
2.51
2.35
0.00
Sales & Valuation
$4.06M
65.28
-15.30
-4.63
-0.80
Profitability
-$1.65
-$50.22M
-2454.64%
-2454.64%
380.80%
-118.34%
P/E Metrics
-3.13
-0.04
-0.04
Analyst Price Target & Rating
$12.00
$12.00
$12.00
2/5
11 Analysts
-60.50%
Poll Results
About Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) Stock
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development an ... d commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
2026-07-16 15:22:00
NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
2026-06-29 08:00:00
Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58 Recent studies advanced science of molecular diagnostic testing for transplanted organ rejection, published in Clinical Chemistry, Transplant International, American Journal of Transplantation and Nephrology Dialysis Transplantation, among others NASHVILLE, Tenn., June 29, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that its Chief Science Officer, Prof.
2026-06-22 14:07:00
-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-
2026-06-16 16:05:00
NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX) ("iMDx") today announced the online publication of a favorable article in Clinical Chemistry, the premier, peer-reviewed scientific publication of the Association for Diagnostics & Laboratory Medicine. The article highlights the concordant performance between iMDx's digital-PCR-based flagship transplant monitoring test, GraftAssure™, and a competing next-generation-sequencing-based assay kit that is sold outside of the U.S.
2026-06-11 16:17:27
American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA alone GraftAssure assay doubles reliability of positive results in screening cohort In for-cause testing of kidney transplant patients, the positive predictive value using the CM-Score increased to greater than 80% NASHVILLE, Tenn.
2026-06-11 16:17:00
NASHVILLE, Tenn., June 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced an online published article in the American Journal of Transplantation asserting statistical superiority of the company's flagship GraftAssure transplant rejection monitoring assay.
Insight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks Transcript
2026-06-11 15:42:09
Insight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks Transcript
2026-06-09 16:05:00
NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced it will be highlighting its GraftAssure™ technology at the upcoming American Transplant Congress, to be held in Boston from Saturday, June 20th through Wednesday, June 24th.
Frequently Asked Questions
-
What is the current Insight Molecular Diagnostics Inc. (IMDX) stock price?
-
Insight Molecular Diagnostics Inc.(NASDAQ:IMDX) stock price is $4.74 in the last trading session. During the trading session, IMDX stock reached the peak price of $8.51 while $2.33 was the lowest point it dropped to. The percentage change in IMDX stock occurred in the recent session was 0.64% while the dollar amount for the price change in IMDX stock was $0.03.
-
IMDX's industry and sector of operation?
-
The NASDAQ listed IMDX is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of IMDX?
-
Ekkehard Schutz | Chief Science Officer
Joshua Riggs | President, Chief Executive Officer & Director
James Liu | Vice President of Accounting, Treasurer, Controller & Principal Accounting Officer
Peter Hong | Vice President, General Counsel & Secretary
Michael D. West | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. -
How many employees does IMDX have?
-
Number of IMDX employees currently stands at 58. IMDX operates from 2 International Plaza Dr., Nashville, TN 92618, US.
-
Link for IMDX official website?
-
Official Website of IMDX is: https://imdxinc.com
-
How do I contact IMDX?
-
IMDX could be contacted at phone #949 409 7600 and can also be accessed through its website. IMDX operates from 2 International Plaza Dr., Nashville, TN 92618, US.
-
How many shares of IMDX are traded daily?
-
The average number of IMDX shares traded daily for last 3 months was 349.82K.
-
What is the market cap of IMDX currently?
-
The market value of IMDX currently stands at $127.23M with its latest stock price at $4.74